A new pill that could offer a cure for hepatitis C has been launched in the UK.
The drug, known as 'daclatasvir' can rid 90% of patients of the diseas within 12 weeks when used with other agents.
Used with another drug, sofosbuvir, it has produced clinical cure rates of 89% and 98% in patients with different viral strains
This is an improvement on the typical cure rate of 60-80% using current treatment methods, which involve injections of the immune system stimulator interferon.
The chair of the Hepatitic C Trust, Charles Gore, said he was "delighted" by the announcement.
"Each new treatment for hepatitis C takes us closer to making the elimination of hepatitis C a realistic possibility, by improving both cure rates and tolerability," he said.